23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral... | April 14, 2023

Related Keywords

United States ,American , ,Nasdaq ,Head Of Therapeutics Development ,American Association For Cancer Research ,Eastern Cooperative Oncology Group ,Me Holding Co ,American Association ,Cancer Research ,Annual Meeting ,Jennifer Low ,Therapeutics Development ,23andme Holding Co Stock Exchange ,News ,Information ,Press Release ,First ,Linical ,Results ,O ,The ,Resented ,It ,He ,Racr ,Nnual ,Meeting ,023 ,Howed ,Remonstrated ,N ,Unacceptable ,Safety ,End ,Tolerability ,Ith ,Favorable ,Pharmacokinetics ,Nd Me Us90138q1085 ,